Roche's targeted cancer drug Kadcyla Japan has been approved

, a Japanese drugmaker controlled by Roche, has approved the HER2 targeted drug Kadcyla as its target drug, Trastuzumab emtansine, according to a recent announcement by Japan's Ministry of Health, Labour and Industry (MHLW). Complementary therapy treats an additional indication of HER2-positive early breast cancer (eBC) patients, specifically for assisted (postoperative) treatment of HER2-positive early breast cancer (eBC) patients with residual immersion disease after receiving new assisted (preoperative) treatment. In the United States and the European Union, Kadcyla was approved in May and December 2019, respectively., Kadcyla approved the treatment of non-excisive or relapsed HER2-positive breast cancer patients. With this latest approval, Kadcyla will provide a new treatment to improve prognosis for HER2-positive early breast cancer patients who receive new assisted (preoperative) treatment without pathological complete remission (pCR).this approval, based on data from the Open Label, Random, Global Phase III KATHERINE Study. The study was conducted in 1,486 patients with HER2-positive early breast cancer who received new complementary therapy (including Herceptin) without pathological complete remission (pCR) and assessed the efficacy and safety of Kadcyla for complementary (postoperative) therapy.results showed that Kadcyla-assisted therapy showed superiority over Hessetine-assisted therapy, significantly reducing the risk of recurrence or total cause of death of immersive breast cancer (HR-0.50, 95%CI:0.39-0.64, p<0001) in terms of the main endpoint of non-immersive disease survival (iDFS).three years of treatment, 83.3 percent of patients in the Kadcyla treatment group did not have a recurrence of breast cancer, compared with 77.0 percent in the Hersheytine treatment group, an absolute improvement of 11.3 percent. In this study, Kadcyla's safety was consistent with previously observed in the previously approved her2-positive metastasis breast cancer treatment, and Kadcyla was also well-to-do as an auxiliary treatment for HER2-positive early breast cancer.early stage breast cancer (eBC) is to provide patients with the best chance of treatment as part of a comprehensive treatment that may involve pre- and post-those treatments. Although we approach this goal every step of the way, many patients still have a recurrence of the disease over the long term. New complementary treatments are given before surgery to reduce tumors and help improve surgical outcomes, and post-surgery complementary treatments are designed to eliminate any remaining cancer cells in the body to help reduce the risk of cancer recurrence.Kadcyla is one of three innovative drugs developed by Roche for the HER2 signaling path, the other two being Hessetin and Perjeta. The launch of these three drugs has transformed the clinical treatment model for HER2-positive breast cancer. HER2-positive breast cancer is a particularly aggressive form of breast cancer that affects about 15-20% of breast cancer patients. For early stage breast cancer (eBC), the purpose of the new auxiliary (preoperative) treatment is to reduce tumor volume and make it easier to surgically remove, and the purpose of the assisted (postoperative) treatment is to eliminate any residual cancer cells to reduce the risk of cancer recurrence.Kadcyla, a HER2 targeted therapy that was approved in 2013 and has been approved by more than 100 countries worldwide to date, is the first and only antibody drug combination (ADC) approved as a single agent for the treatment of HER2-positive metastasis breast cancer patients who have previously received chemotherapy (single or combination therapy) for Hercetin and yew. The drug is made up of trastuzumab, the active drug ingredient of Hessetin, and ImmunoGen's cytotoxic agent DM1, which is delivered to HER2-positive breast cancer cells via a stable link. Kadcyla has two anti-cancer properties: HER2 inhibition of crater bead monoantigen and cytotoxicity of DM1.
(Bio Valley)